What is Sana Biotechnology, Inc.'s earnings per share (EPS)?

Sana Biotechnology, Inc. (SANA) reported diluted earnings per share of $-0.96 for fiscal year 2025. This represents a 17.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Sana Biotechnology, Inc. Financials

SANA

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Sana Biotechnology, Inc. (SANA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

Sana Biotechnology, Inc. passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.59x

For every $1 of reported earnings, Sana Biotechnology, Inc. generates $0.59 in operating cash flow (-$143.8M OCF vs -$244.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$237.5M

YoY+7.7%

Sana Biotechnology, Inc.'s EBITDA was -$237.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 7.7% from the prior year.

Net Income

-$244.2M

YoY+8.5%

Sana Biotechnology, Inc. reported -$244.2M in net income in fiscal year 2025. This represents an increase of 8.5% from the prior year.

EPS (Diluted)

$-0.96

YoY+17.2%

Sana Biotechnology, Inc. earned $-0.96 per diluted share (EPS) in fiscal year 2025. This represents an increase of 17.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$144.8M

YoY+43.6%

Sana Biotechnology, Inc. generated -$144.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 43.6% from the prior year.

Cash & Debt

$71.9M

YoY-43.7%

5Y CAGR-10.5%

Sana Biotechnology, Inc. held $71.9M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

267M

YoY+19.1%

Sana Biotechnology, Inc. had 267M shares outstanding in fiscal year 2025. This represents an increase of 19.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-151.8%

YoY-45.3pp

Sana Biotechnology, Inc.'s ROE was -151.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 45.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$132.0M

YoY-38.8%

5Y CAGR-0.1%

Sana Biotechnology, Inc. invested $132.0M in research and development in fiscal year 2025. This represents a decrease of 38.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$938K

YoY-97.2%

5Y CAGR-47.7%

Sana Biotechnology, Inc. invested $938K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 97.2% from the prior year.

SANA Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$132.0M-38.8%	$215.7M-17.6%	$261.8M-8.4%	$285.9M+15.0%	$248.6M+87.0%	$132.9M
SG&A Expenses	$44.3M-30.8%	$64.0M-12.6%	$73.3M+2.4%	$71.6M+42.0%	$50.4M+78.3%	$28.3M
Operating Income	-$250.3M+8.2%	-$272.7M+7.0%	-$293.1M-7.5%	-$272.6M+23.6%	-$356.9M-24.7%	-$286.1M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	N/A	N/A	N/A	N/A	N/A
Net Income	-$244.2M+8.5%	-$266.8M+5.8%	-$283.3M-5.1%	-$269.5M+24.3%	-$355.9M-24.8%	-$285.3M
EPS (Diluted)	$-0.96+17.2%	$-1.16+20.5%	$-1.46-2.1%	$-1.43+33.2%	$-2.14	$-21.92

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$30.1M+1.2%	$29.8M-20.0%	$37.2M	N/A	$53.2M-12.6%	$60.9M+7.8%	$56.4M
SG&A Expenses	N/A	$10.3M-0.5%	$10.3M-10.0%	$11.5M	N/A	$14.1M-14.5%	$16.4M+1.1%	$16.3M
Operating Income	N/A	-$43.5M+54.2%	-$95.0M-87.6%	-$50.6M	N/A	-$61.8M-25.1%	-$49.4M+55.4%	-$110.7M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$42.2M+55.1%	-$93.8M-89.9%	-$49.4M	N/A	-$59.9M-19.2%	-$50.3M+53.2%	-$107.5M
EPS (Diluted)	N/A	$-0.16+59.0%	$-0.39-85.7%	$-0.21	N/A	$-0.25-19.0%	$-0.21+57.1%	$-0.49

SANA Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$416.9M-16.8%	$501.0M-11.4%	$565.3M-31.3%	$822.7M-27.2%	$1.1B+54.7%	$730.3M
Current Assets	$148.7M-7.5%	$160.8M-24.7%	$213.5M-52.0%	$444.4M-20.4%	$558.1M+45.2%	$384.5M
Cash & Equivalents	$71.9M-43.7%	$127.6M-4.5%	$133.5M-24.5%	$176.8M-30.1%	$253.0M+102.7%	$124.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$140.6M0.0%	$140.6M0.0%	$140.6M0.0%	$140.6M0.0%	$140.6M0.0%	$140.6M
Total Liabilities	$256.0M+2.2%	$250.5M-9.8%	$277.8M-14.1%	$323.4M-19.3%	$400.9M-65.2%	$1.2B
Current Liabilities	$78.7M+73.3%	$45.4M-29.5%	$64.5M-42.2%	$111.5M+12.4%	$99.2M+215.5%	$31.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$160.9M-35.8%	$250.5M-12.9%	$287.5M-42.4%	$499.3M-31.5%	$728.5M+273.0%	-$421.2M
Retained Earnings	-$1.8B-15.2%	-$1.6B-19.9%	-$1.3B-26.9%	-$1.1B-34.3%	-$785.4M-82.9%	-$429.4M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$416.9M-4.3%	$435.4M+20.4%	$361.6M-18.8%	$445.5M-11.1%	$501.0M-10.4%	$559.4M-9.6%	$618.7M-9.2%	$681.4M
Current Assets	$148.7M-8.1%	$161.8M+96.1%	$82.5M-26.8%	$112.7M-29.9%	$160.8M-23.5%	$210.1M-20.2%	$263.5M-18.0%	$321.3M
Cash & Equivalents	$71.9M-30.5%	$103.4M+45.0%	$71.3M-25.9%	$96.1M-24.6%	$127.6M+0.4%	$127.0M-5.9%	$135.0M-23.8%	$177.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$140.6M0.0%	$140.6M0.0%	$140.6M0.0%	$140.6M0.0%	$140.6M0.0%	$140.6M0.0%	$140.6M0.0%	$140.6M
Total Liabilities	$256.0M+6.6%	$240.1M+0.4%	$239.1M+1.1%	$236.4M-5.6%	$250.5M-6.1%	$266.9M-4.3%	$279.0M-8.9%	$306.2M
Current Liabilities	$78.7M+121.7%	$35.5M+6.2%	$33.4M+0.9%	$33.2M-27.0%	$45.4M-3.3%	$47.0M-7.3%	$50.7M-4.2%	$52.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$160.9M-17.6%	$195.3M+59.4%	$122.6M-41.4%	$209.1M-16.5%	$250.5M-14.4%	$292.5M-13.9%	$339.6M-9.5%	$375.1M
Retained Earnings	-$1.8B-3.3%	-$1.8B-2.4%	-$1.7B-5.7%	-$1.7B-3.1%	-$1.6B-3.2%	-$1.6B-4.0%	-$1.5B-3.5%	-$1.4B

SANA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$143.8M+35.5%	-$223.2M+12.0%	-$253.6M+12.6%	-$290.1M-15.5%	-$251.1M-81.9%	-$138.0M
Capital Expenditures	$938K-97.2%	$33.4M+66.9%	$20.0M-4.0%	$20.9M-30.1%	$29.9M+25.1%	$23.9M
Free Cash Flow	-$144.8M+43.6%	-$256.6M+6.2%	-$273.6M+12.0%	-$310.9M-10.7%	-$280.9M-73.6%	-$161.9M
Investing Cash Flow	-$40.2M-330.6%	$17.5M-89.9%	$172.0M-18.3%	$210.6M+185.7%	-$245.8M+2.7%	-$252.6M
Financing Cash Flow	$128.7M-35.6%	$199.7M+531.2%	$31.6M+544.1%	$4.9M-99.2%	$631.8M+45.0%	$435.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$32.6M-10.9%	-$29.4M+11.1%	-$33.1M+32.0%	-$48.7M-3.2%	-$47.2M+9.0%	-$51.8M+11.5%	-$58.5M+10.8%	-$65.6M
Capital Expenditures	$873K+2029.3%	$41K+136.6%	-$112K-182.4%	$136K-68.8%	$436K-89.3%	$4.1M-68.7%	$13.1M-17.6%	$15.8M
Free Cash Flow	-$33.5M-13.7%	-$29.5M+11.3%	-$33.2M+31.9%	-$48.8M-2.5%	-$47.6M+14.9%	-$55.9M+21.9%	-$71.6M+12.1%	-$81.5M
Investing Cash Flow	-$16.5M+65.7%	-$48.0M-725.3%	$7.7M-53.7%	$16.6M-64.7%	$47.1M+12.7%	$41.8M+618.0%	$5.8M+107.5%	-$77.2M
Financing Cash Flow	$17.6M-83.9%	$109.5M+19425.8%	$561K-42.9%	$982K+52.7%	$643K-69.1%	$2.1M-80.4%	$10.6M-94.3%	$186.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SANA Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-151.8%-45.3pp	-106.5%-8.0pp	-98.5%-44.5pp	-54.0%-5.1pp	-48.9%	N/A
Return on Assets	-58.6%-5.3pp	-53.2%-3.1pp	-50.1%-17.4pp	-32.8%-1.2pp	-31.5%+7.6pp	-39.1%
Current Ratio	1.89-1.7	3.54+0.2	3.31-0.7	3.99-1.6	5.62-6.6	12.22
Debt-to-Equity	1.59+0.6	1.00+0.0	0.97+0.3	0.65+0.1	0.55+3.3	-2.73
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-21.6%+55.0pp	-76.5%-52.9pp	-23.6%	N/A	-20.5%-5.7pp	-14.8%+13.8pp	-28.6%
Return on Assets	N/A	-9.7%+16.3pp	-25.9%-14.9pp	-11.1%	N/A	-10.7%-2.6pp	-8.1%+7.6pp	-15.8%
Current Ratio	1.89-2.7	4.55+2.1	2.47-0.9	3.40-0.1	3.54-0.9	4.47-0.7	5.20-0.9	6.07
Debt-to-Equity	1.59+0.4	1.23-0.7	1.95+0.8	1.13+0.1	1.00+0.1	0.91+0.1	0.820.0	0.82
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Nektar Therapeutics NKTR

$2.2B

Iovance Biotherp IOVA

$1.4B

Uniqure QURE

$1.1B

Urogen Pharma URGN

$916.2M

Taysha Gene Therapies, Inc. TSHA

$1.3B

Frequently Asked Questions

Is Sana Biotechnology, Inc. profitable?

No, Sana Biotechnology, Inc. (SANA) reported a net income of -$244.2M in fiscal year 2025.

What is Sana Biotechnology, Inc.'s EBITDA?

Sana Biotechnology, Inc. (SANA) had EBITDA of -$237.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Sana Biotechnology, Inc.'s return on equity (ROE)?

Sana Biotechnology, Inc. (SANA) has a return on equity of -151.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Sana Biotechnology, Inc.'s free cash flow?

Sana Biotechnology, Inc. (SANA) generated -$144.8M in free cash flow during fiscal year 2025. This represents a 43.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Sana Biotechnology, Inc.'s operating cash flow?

Sana Biotechnology, Inc. (SANA) generated -$143.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Sana Biotechnology, Inc.'s total assets?

Sana Biotechnology, Inc. (SANA) had $416.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Sana Biotechnology, Inc.'s capital expenditures?

Sana Biotechnology, Inc. (SANA) invested $938K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Sana Biotechnology, Inc. spend on research and development?

Sana Biotechnology, Inc. (SANA) invested $132.0M in research and development during fiscal year 2025.

How many shares does Sana Biotechnology, Inc. have outstanding?

Sana Biotechnology, Inc. (SANA) had 267M shares outstanding as of fiscal year 2025.

What is Sana Biotechnology, Inc.'s current ratio?

Sana Biotechnology, Inc. (SANA) had a current ratio of 1.89 as of fiscal year 2025, which is generally considered healthy.

What is Sana Biotechnology, Inc.'s debt-to-equity ratio?

Sana Biotechnology, Inc. (SANA) had a debt-to-equity ratio of 1.59 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Sana Biotechnology, Inc.'s return on assets (ROA)?

Sana Biotechnology, Inc. (SANA) had a return on assets of -58.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Sana Biotechnology, Inc.'s cash runway?

Based on fiscal year 2025 data, Sana Biotechnology, Inc. (SANA) had $71.9M in cash against an annual operating cash burn of $143.8M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Sana Biotechnology, Inc.'s Piotroski F-Score?

Sana Biotechnology, Inc. (SANA) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Sana Biotechnology, Inc.'s earnings high quality?

Sana Biotechnology, Inc. (SANA) has an earnings quality ratio of 0.59x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.